Lovotibeglogene autotemcel is an autologous CD34+ cell therapy used to treat sickle cell disease by providing a functional copy of the beta-globin gene. Lovotibeglogene autotemcel consists of autologous hematopoietic stem and progenitor cells transduced with the BB305 lentiviral vector encoding a modified β-globin gene.
- Mechanism
- Curator reviewed · 1 reference
Lovotibeglogene autotemcel adds functional copies of a modified βA-globin gene (threonine [T] replaced with glutamine Q at position 87, T87Q or βA-T87Q-globin) into patients’ hematopoietic stem cells (HSCs) through transduction of autologous CD34+ cells with BB305 LVV.
- Primary indication
- Lovotibeglogene autotemcel is indicated for the treatment of patients 12 years of age or older with sickle cell disease and a history of vaso-occlusive events.Curator reviewed · 1 structured indication
- First approval
- United States, 2023
- Also known as
- Lovo-cel
- Code names
- bb1111
- Brand names
Resolves to
What you can answer from here — as of June 15, 2026
Which drugs share a target with Lovotibeglogene autotemcel, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account